Siemens Healthineers Announces FDA Clearance of New Version of Molecular Imaging Software

Jun 08, 2017

· Latest release of syngo.via VB20 for Molecular Imaging simplifies workflows and enhances ease-of-use for PET and SPECT

· Brand-new Multi-Foci Segmentation feature enables automatic calculation of patient’s whole-body tumor burden for therapy assessment

 

The Food and Drug Administration (FDA) has cleared syngo.via VB20 for Molecular Imaging (MI) from Siemens Healthineers – a new release of the company’s established intelligent visualization software for multi-modality imaging. This latest version of syngo.via VB20 for MI contains dynamic new features and improvements designed to simplify workflows and enhance ease-of-use in positron emission tomography (PET) and single-photon emission computed tomography (SPECT). With software such as syngo.via VB20 for MI and a new name that underlines the company’s pioneering spirit and engineering expertise, Siemens Healthineers – the separately managed healthcare business of Siemens AG – helps healthcare providers worldwide meet current challenges and excel in their respective environments.

 

The software’s brand-new Multi-Foci Segmentation (MFS) feature for PET and SPECT permits automatic, one-click calculation of a patient’s whole-body tumor burden. Some clinicians leverage this calculation to assess patient response to therapy through reproducible quantification of the total tumor. Historically, this calculation has been performed manually and can be time-consuming.

 

The improved MI OncoBoard feature of syngo.via VB20 for MI displays pre-therapy and post-therapy treatment responses simultaneously, potentially enhancing understanding of disease progression and informing discussion during offline tumor board meetings.

 

Finally, the improved MI Neurology feature of syngo.via VB20 for MI has two new capabilities. Users can now compare data from two different time points – similar to the new MI OncoBoard feature – to gauge disease progression. Also, clinicians can not only visualize and quantify patient uptake of certain amyloid radiopharmaceutical, but they also can compare the scanned patient with a database of normal patients to provide value to quantification numbers.

 

 

Contact for journalists

Jeff Bell

Phone: (484) 868-8346; E-mail: jeffrey.t.bell@siemens-healthineers.com

 

Siemens Healthineers is the separately managed healthcare business of Siemens AG enabling healthcare providers worldwide to meet their current challenges and to excel in their respective environments. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. To help customers succeed in today’s dynamic healthcare marketplace, Siemens Healthineers is championing new business models that maximize opportunity and minimize risk for healthcare providers.
In fiscal 2016, which ended on September 30, 2016, Siemens Healthineers generated revenue of €13.5 billion and profit of over €2.3 billion and has about 46,000 employees worldwide. Further information is available at www.siemens.com/healthineers.